Search for a trial

CER-001 Infusions in Subjects with Familial HDL-c Deficiency

Evaluate the effects of CER-001 - adminstered as iv infusion - on plaque size/burden in arteries, plaque inflammation in the artery wall and the rate of cholesterol transport in the body

A phase II multi-centre, double blind, placebo-controlled, dose focusing trial of CER-001 or placebo in subjects with Acute Coronary Syndrome (CER-001-CLIN-010, CARAT study)

To assess the impact of 10 intravenous infusions of 3 mg/kg CER-001 versus placebo, given at weekly intervals, on atherosclerotic plaque volume, as measured by coronary IVUS, when administered to subjects presenting with an ACS event.